A Day in the Life of a Cell Therapy Specialist at Kite, a Gilead Company
A Day in the Life of a Cell Therapy Specialist at Kite, a Gilead Company
5 Questions with Nesha Miller, Director, Supply Chain, Kite Pharma
5 Questions with Nesha Miller, Director, Supply Chain, Kite Pharma November 14, 2023 1. Tell us about your career path leading up to your current role at Kite. I studied [….]
Kite Pharma Recognized as Life Science Company of the Year at 2023 ICON Awards
(SOURCE: Maryland Tech Council) Kite Pharma Recognized as Life Science Company of the Year at the 2023 ICON Awards By Sarah EllinwoodApril 28, 2023 On April 27, leaders from around [….]
Here Are Several BioHealth Capital Region Life Science Companies Hiring Right Now: Q2 2023
Here Are Several BioHealth Capital Region Life Science Companies Hiring Right Now: Q2 2023 By Alex KeownApril 13, 2023 Companies within the BioHealth Capital Region hub are hiring for multiple [….]
In a Recent M&A Desert, Philly Proves to Be an Oasis
There have been two big recent mergers-and-acquisitions involving Philadelphia life science companies. Today, Philadelphia’s Adaptimmune announced a merger with TCR2 Therapeutics. And about two weeks ago, the acquisition of Philly’s Tmunity by Gilead’s Kite closed. Let’s take a closer look at these deals and what it means for the growing Philly cell and gene therapy community.
Kite And Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Kite to Add 100 New Jobs in Frederick County With Expansion of Cell Therapy Manufacturing Operations
Kite, a Gilead Company, announced plans to expand its global cell therapy supply chain operations in Frederick County, Maryland. This year, the California-based company will begin construction on an approximately 70,000 square-foot centralized raw materials warehouse that will serve Kite’s global manufacturing network and will be located adjacent to its existing facility in the Urbana Corporate Center. The expansion will bring an additional 100 jobs to the area, with the company expecting to employ more than 500 full-time staff between its two facilities by the end of 2026.
Greater Philadelphia Q4 2022 News Recap – December was a Pivotal Month for Cellicon Valley Companies
Cellicon Valley companies closed out 2022 with a roar. Madrigal Pharmaceuticals announced a breakthrough in NASH that could result in the first-approved drug for that disease. Galera Therapeutics closed out December with plans to seek approval for its severe oral mucositis therapy.
Kite to Bolster Cell Therapy Capabilities through Acquisition of Carl June’s Tmunity Therapeutics
A Gilead Sciences company, Kite announced Tmunity’s next-generation CAR-T therapies and technology will complement its own cell therapy research capabilities. Kite’s acquisition of Tmunity, founded by Carl June, creates a strong bridge between the BioHealth Capital Region, where Kite maintains its manufacturing capabilities in Frederick, and the Greater Philadelphia biohub.
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a strategic research and licensing agreement with the University of Pennsylvania (Penn).